Cost-effectiveness of a digital supportive healthcare pathway for type 2 diabetes compared to usual care in Belgium
- Author
- Lisa Van Wilder (UGent) , Delphine De Smedt (UGent) , Lieselotte Sandra, Dorien Vandormael, Joyce Kaes, Ruben Willems (UGent) and Jeroen Trybou (UGent)
- Organization
- Abstract
- Objective. To evaluate the cost-effectiveness of a digital supportive healthcare pathway in patients with type 2 diabetes mellitus (T2DM) compared to usual care. Methods. An age-dependent Markov model was applied from a healthcare payer perspective projecting results of a clinical trial study over a time horizon of 22 years assuming a continuous implementation of the intervention every year, 24/7. The setting was Flanders (Belgium). One-way and probabilistic sensitivity analyses were performed. Results. The hybrid care pathway led to a quality-adjusted life year (QALY) gain of 5.97, while the costs increased with €663,036. This resulted in an incremental cost-effectiveness ratio of €110,989/QALY. With a cost-effectiveness threshold of 45,000€/QALY, the hybrid care pathway was found not cost-effective compared to the usual care trajectory. Sensitivity analyses showed that over 50\% of iterations exceeded the threshold, with a cost-effectiveness probability of 13.12% at €45,000/QALY. Conclusions. This cost-effectiveness analysis indicates that a hybrid care pathway is unlikely to be a cost-effective approach compared to the standard care trajectory in patients with T2DM. Nevertheless, the exploration of technology-driven healthcare pathways are vital for advancing patient well-being, emphasizing the need for further research to optimize resource utilization and enhance outcomes effectively.
- Keywords
- Type 2 diabetes mellitus, cost-effectiveness, digital health, hybrid care, COMPLICATIONS, IMPACT, TRANSFERABILITY, GUIDELINES
Downloads
-
van-wilder-et-al-2025-version of record.pdf
- full text (Published version)
- |
- open access
- |
- |
- 1.11 MB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-01JN3EMCTGT0WDASPY2G07B7KP
- MLA
- Van Wilder, Lisa, et al. “Cost-Effectiveness of a Digital Supportive Healthcare Pathway for Type 2 Diabetes Compared to Usual Care in Belgium.” DIGITAL HEALTH, vol. 11, 2025, doi:10.1177/20552076251319169.
- APA
- Van Wilder, L., De Smedt, D., Sandra, L., Vandormael, D., Kaes, J., Willems, R., & Trybou, J. (2025). Cost-effectiveness of a digital supportive healthcare pathway for type 2 diabetes compared to usual care in Belgium. DIGITAL HEALTH, 11. https://doi.org/10.1177/20552076251319169
- Chicago author-date
- Van Wilder, Lisa, Delphine De Smedt, Lieselotte Sandra, Dorien Vandormael, Joyce Kaes, Ruben Willems, and Jeroen Trybou. 2025. “Cost-Effectiveness of a Digital Supportive Healthcare Pathway for Type 2 Diabetes Compared to Usual Care in Belgium.” DIGITAL HEALTH 11. https://doi.org/10.1177/20552076251319169.
- Chicago author-date (all authors)
- Van Wilder, Lisa, Delphine De Smedt, Lieselotte Sandra, Dorien Vandormael, Joyce Kaes, Ruben Willems, and Jeroen Trybou. 2025. “Cost-Effectiveness of a Digital Supportive Healthcare Pathway for Type 2 Diabetes Compared to Usual Care in Belgium.” DIGITAL HEALTH 11. doi:10.1177/20552076251319169.
- Vancouver
- 1.Van Wilder L, De Smedt D, Sandra L, Vandormael D, Kaes J, Willems R, et al. Cost-effectiveness of a digital supportive healthcare pathway for type 2 diabetes compared to usual care in Belgium. DIGITAL HEALTH. 2025;11.
- IEEE
- [1]L. Van Wilder et al., “Cost-effectiveness of a digital supportive healthcare pathway for type 2 diabetes compared to usual care in Belgium,” DIGITAL HEALTH, vol. 11, 2025.
@article{01JN3EMCTGT0WDASPY2G07B7KP,
abstract = {{Objective. To evaluate the cost-effectiveness of a digital supportive healthcare pathway in patients with type 2 diabetes mellitus (T2DM) compared to usual care.
Methods. An age-dependent Markov model was applied from a healthcare payer perspective projecting results of a clinical trial study over a time horizon of 22 years assuming a continuous implementation of the intervention every year, 24/7. The setting was Flanders (Belgium). One-way and probabilistic sensitivity analyses were performed.
Results. The hybrid care pathway led to a quality-adjusted life year (QALY) gain of 5.97, while the costs increased with €663,036. This resulted in an incremental cost-effectiveness ratio of €110,989/QALY. With a cost-effectiveness threshold of 45,000€/QALY, the hybrid care pathway was found not cost-effective compared to the usual care trajectory. Sensitivity analyses showed that over 50\% of iterations exceeded the threshold, with a cost-effectiveness probability of 13.12% at €45,000/QALY.
Conclusions. This cost-effectiveness analysis indicates that a hybrid care pathway is unlikely to be a cost-effective approach compared to the standard care trajectory in patients with T2DM. Nevertheless, the exploration of technology-driven healthcare pathways are vital for advancing patient well-being, emphasizing the need for further research to optimize resource utilization and enhance outcomes effectively.}},
articleno = {{20552076251319169}},
author = {{Van Wilder, Lisa and De Smedt, Delphine and Sandra, Lieselotte and Vandormael, Dorien and Kaes, Joyce and Willems, Ruben and Trybou, Jeroen}},
issn = {{2055-2076}},
journal = {{DIGITAL HEALTH}},
keywords = {{Type 2 diabetes mellitus,cost-effectiveness,digital health,hybrid care,COMPLICATIONS,IMPACT,TRANSFERABILITY,GUIDELINES}},
language = {{eng}},
pages = {{13}},
title = {{Cost-effectiveness of a digital supportive healthcare pathway for type 2 diabetes compared to usual care in Belgium}},
url = {{http://doi.org/10.1177/20552076251319169}},
volume = {{11}},
year = {{2025}},
}
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: